Weight & metabolic
Orforglipron
Oral GLP-1 Receptor Agonist
The first small-molecule GLP-1 pill, and the only one with no food or water restrictions. A daily pill from Eli Lilly (brand Foundayo) that provides similar benefits to injectable GLP-1s without needles.
Also known as: LY3502970, oral GLP-1
- Status
- Orforglipron is approved by the U.S. FDA and has official prescribing information.
- Evidence
- Human trials. Published clinical trials in people report results.
- Half-life
- ~24-36 hours
- How it's taken
- Daily oral pill
- Mechanism
- Incretin (GLP-1 / GIP / glucagon / amylin)
- Pathways
- GLP-1
How Orforglipron works
A small molecule (non-peptide) that activates GLP-1 receptors the same way injectable peptides do, but is stable enough to survive stomach acid and be absorbed through the gut. No special timing or fasting required.
What research has looked at
- Oral pill — no injections needed
- No food or water restrictions when taking
- Significant weight loss comparable to injectables
- Daily dosing for consistent levels
Evidence level: Human trials. Published clinical trials in people report results. These are areas studied or reported, not promised effects.
Reported side effects and risks
- Nausea (most common)
- Vomiting
- Diarrhea
- Constipation
- Abdominal pain
- Similar GI profile to injectable GLP-1s
Sources
- FDA approved-drug listing for orforglipron · U.S. Food & Drug Administration
- Active clinical trials for orforglipron · U.S. National Library of Medicine
- PubMed research on orforglipron oral GLP-1 agonist · NIH · National Library of Medicine
- DrugBank record for orforglipron · DrugBank
Track Orforglipron in Peptide Vault
Log every dose, set reminders on your own schedule, rotate injection sites and keep your vials organized. Peptide Vault records what you enter. It doesn't recommend compounds or doses. iPhone, on-device.
Related compounds
Orforglipron FAQ
What is Orforglipron?
The first small-molecule GLP-1 pill, and the only one with no food or water restrictions. A daily pill from Eli Lilly (brand Foundayo) that provides similar benefits to injectable GLP-1s without needles.
How does Orforglipron work?
A small molecule (non-peptide) that activates GLP-1 receptors the same way injectable peptides do, but is stable enough to survive stomach acid and be absorbed through the gut. No special timing or fasting required.
Is Orforglipron FDA approved?
Yes. Orforglipron is approved by the U.S. FDA and has official prescribing information. Evidence level: human trials. Published clinical trials in people report results.
What is the half-life of Orforglipron?
Reported half-life: ~24-36 hours.
How is Orforglipron taken?
Daily oral pill.
What side effects have been reported with Orforglipron?
Reported in the sources: Nausea (most common); Vomiting; Diarrhea; Constipation; Abdominal pain; Similar GI profile to injectable GLP-1s.
Educational summary compiled from the sources listed above. Not medical advice. Peptide Vault does not sell, source or recommend any compound. Talk to a qualified clinician before starting or changing anything.